Please use this identifier to cite or link to this item: http://repository.pdmu.edu.ua/handle/123456789/17959
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShynkevych, Viktoriia-
dc.contributor.authorKolomiiets, Svitlana-
dc.contributor.authorKaidashev, Igor-
dc.contributor.authorШинкевич, Вікторія Ігорівна-
dc.contributor.authorКоломієць, Світлана Веніамінівна-
dc.contributor.authorКайдашев, Ігор Петрович-
dc.date.accessioned2022-04-07T07:01:34Z-
dc.date.available2022-04-07T07:01:34Z-
dc.date.issued2021-11-09-
dc.identifier.citationShynkevych V. I. Effects of l-arginine and l-ornithine supplementations on the treatment of chronic periodontitis: A preliminary randomized short-term clinical trial / V. I. Shynkevych, S. V. Kolomiiets, I. P. Kaidashev // Heliyon. – 2021. – Vol. 7, № 11. – e08353. doi: 10.1016/j.heliyon.2021.e08353. PMID: 34816043; PMCID: PMC8593455.uk_UA
dc.identifier.urihttp://repository.pdmu.edu.ua/handle/123456789/17959-
dc.description.abstractAbstract The growing interest in the possibilities of modulating macrophages in inflammatory diseases with therapeutic purpose has prompted the development of new approaches for the treatment of periodontitis. This randomized add-on open preliminary clinical study evaluated the short-term effects of L-arginine or L-ornithine as an adjuvant to scaling and root planing (SRP) in patients with chronic periodontitis. Materials and methods Seventy-five periodontitis patients were recruited and monitored clinically and immunologically at baseline (before SRP) and 30 ± 5 days after SRP. All patients were assigned by stratified randomization to SRP (SRP only, n = 25), Arg (SRP + L-arginine, n = 25) or Control (SRP + L-ornithine, n = 25) Group. The medicines were used according to available instructions for 10 and 15 days, respectively. During the study, all patients were on a stable diet, without changing their rations and regiments. As immunological monitoring immunohistochemical study of CD68+ and CD163 + single positive gingival macrophages for 5 patients per group in the same time-point was conducted. The data were statistically analyzed. Results Reduction of periodontal pocket depth (PPD) and bleeding on probing (BoP) was observed in all groups, with significant between-group differences for BoP in the Arg Group (p < 0.0001) at 30 days. The SRP and Arg groups demonstrated nonsignificantly increased density of CD68+ and CD163 + cells. The Orn Group showed an increase in the density of CD68+ and CD163 + macrophages at intragroup (p = 0.0066 and p < 0.0001) and between-group levels (p = 0.001 and p < 0.0001), and these changes corresponded to clinical PPD and BoP reduction. In the Arg and Orn groups at 30 days, CD163 + macrophages significantly predominated over CD68+ (p = 0.013, p < 0.0001). Conclusion The use of L-arginine and L-ornithine as an adjunct to SRP promotes additional limited immunological benefit in the treatment of periodontitis. Metabolic stimulation with L-ornithine, but not L-arginine, is preferable for CD163+ Mφs subpopulation in periodontitis-affected gingiva.uk_UA
dc.description.sponsorshipThis work is part of the research project No. 0120U101151 “The contribution of components of the molecular clock in the impairment of periodontal tissues in its inflammatory diseases for the development of methods for prevention and treatment” funded by the Ministry of Health of Ukraine.uk_UA
dc.language.isoenuk_UA
dc.publisherElsevier Ltd.uk_UA
dc.subjectCD163+ macrophageuk_UA
dc.subjectCD68+ macrophageuk_UA
dc.subjectclinical trialuk_UA
dc.subjectL-arginineuk_UA
dc.subjectL-ornithineuk_UA
dc.subjectmacrophages-targeted therapyuk_UA
dc.subjectperiodontitisuk_UA
dc.titleEffects of l-arginine and l-ornithine supplementations on the treatment of chronic periodontitis: A preliminary randomized short-term clinical trialuk_UA
dc.typeArticleuk_UA
Appears in Collections:Навчально-методичні видання

Files in This Item:
File Description SizeFormat 
effect_of_l-arginine_and_l-ornithine.pdf2,56 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.